US Edition
Managing Moderate to Severe COPD: Integrating New Therapies Into Practice
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
El Govern de Salvador Illa refuses to withdraw the limit set in the Pharmaceutical Prescription Quality Index (IQF) for prescriptions for triple therapy for COPD (LAMA/LABA/CI combination) based on clinical and efficiency criteria, which opens the door to cost-based restrictions rather than clinical need. Thus, a response from the Catalan Health Service to the National Association of Patients with Chronic Obstructive Pulmonary Disease (APEPOC) t…
Managing Moderate to Severe COPD: Integrating New Therapies Into Practice
Panelists discuss the evolving role of newly approved chronic obstructive pulmonary disease (COPD) therapies—such as ensifentrine, mepolizumab, and dupilumab—in addressing persistent symptoms and frequent exacerbations despite standard care, highlighting their targeted use based on patient profiles, the practical challenges of integration into clinical practice, and the importance of education, shared decision-making, and personalized care to op…
NMPA approves Theravance’s YUPELRI for COPD in China - BioTuesdays
Theravance Biopharma (NASDAQ: TBPH) has announced that China’s National Medical Products Administration (NMPA) has granted regulatory approval for YUPELRI, the company’s revefenacin inhalation solution for the treatment of chronic obstructive pulmonary disease (COPD). YUPELRI is the first once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved for the maintenance treatment of COPD in China. According to Theravance, the approval i…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
